Evidence map›Paper›PMID 28205048›Full record

ArticleJournal of inherited metabolic disease2017

Mild orotic aciduria in UMPS heterozygotes: a metabolic finding without clinical consequences.

Saskia B Wortmann, Margaret A Chen, Roberto Colombo, Alessandro Pontoglio, Bader Alhaddad, Lorenzo D Botto, Tatiana Yuzyuk, Curtis R Coughlin, Maria Descartes, Stephanie Grűnewald and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Increased Environment-Related Metabolism and Genetic Expression in theFrontiers in cell and developmental biology · 2021
    Article
  11. Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation.Genetics in medicine : official journal of the American College of Medical Genetics · 2020
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 9 countries.

Saskia B WortmannDepartment of Pediatrics, Salzburger Landeskliniken (SALK) and Paracelsus Medical University (PMU), Mullner Hauptstrasse 48, 5020, Salzburg, Austria. s.wortmann-hagemann@salk.at.
Margaret A ChenPrevention Genetics, Marshfield, WI, USA.
Roberto ColomboInstitute of Clinical Biochemistry, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
Alessandro PontoglioCenter for the Study of Rare Hereditary Diseases, Niguarda Ca' Granda Metropolitan Hospital, Milan, Italy.
Bader AlhaddadInstitute of Human Genetics, Technical University Munich, Munich, Germany.
Lorenzo D BottoDepartment of Genetics, University of Utah School of Medicine, Salt Lake City, UT, USA.
Tatiana YuzyukDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
Curtis R CoughlinDepartment of Pediatrics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Maria DescartesDepartments of Genetics and Pediatrics, University of Alabama School of Medicine, Birmingham, AL, USA.
Stephanie GrűnewaldMetabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, and UCL Institute of Child Health, London, UK.
Bruno MarandaCHUS Genetic Services, University of Sherbrooke, Sherbrooke, QC, Canada.
Philippa B MillsGenetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health, London, UK.
James PittVictorian Clinical Genetics Services, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Australia.
Catherine PotenteAmbry Genetics, Aliso Viejo, CA, USA.
Richard RodenburgTranslational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Leo A J KluijtmansTranslational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Srirangan SampathPrevention Genetics, Marshfield, WI, USA.
Emil F PaiPrincess Margaret Cancer Centre, and Departments of Biochemistry, Medical Biophysics, and Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Ron A WeversTranslational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
George E TillerDepartment of Genetics, Kaiser Permanente, Los Angeles, CA, USA.
additional individual contributors
Marshfield Clinic · USRadboud University Medical Center · NLUniversity College London · GBAmbry Genetics (United States) · USARUP Laboratories (United States) · USFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITHealth and Social Services Centre University Institute of Geriatrics of Sherbrooke · CAKaiser Permanente · USParacelsus Medical University · ATRadboud University Nijmegen · NLTechnical University of Munich · DEUniversity of Alabama · USUniversity of Colorado Denver · USUniversity of Melbourne · AUUniversity of the Sacred Heart · JPUniversity of Toronto · CAUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElevated urinary excretion of orotic acid is associated with treatable disorders of the urea cycle and pyrimidine metabolism. Establishing the correct and timely diagnosis in a patient with orotic aciduria is key to effective treatment. Uridine monophosphate synthase is involved in de novo pyrimidine synthesis. Uridine monophosphate synthase deficiency (or hereditary orotic aciduria), due to biallelic mutations in UMPS, is a rare condition presenting with megaloblastic anemia in the first months of life. If not treated with the pyrimidine precursor uridine, neutropenia, failure to thrive, growth retardation, developmental delay, and intellectual disability may ensue. METHODS AND

resultsWe identified mild and isolated orotic aciduria in 11 unrelated individuals with diverse clinical signs and symptoms, the most common denominator being intellectual disability/developmental delay. Of note, none had blood count abnormalities, relevant hyperammonemia or altered plasma amino acid profile. All individuals were found to have heterozygous alterations in UMPS. Four of these variants were predicted to be null alleles with complete loss of function. The remaining variants were missense changes and predicted to be damaging to the normal encoded protein. Interestingly, family screening revealed heterozygous UMPS variants in combination with mild orotic aciduria in 19 clinically asymptomatic family members.

conclusionsWe therefore conclude that heterozygous UMPS-mutations can lead to mild and isolated orotic aciduria without clinical consequence. Partial UMPS-deficiency should be included in the differential diagnosis of mild orotic aciduria. The discovery of heterozygotes manifesting clinical symptoms such as hypotonia and developmental delay are likely due to ascertainment bias.

Indexed as

Anemia, MegaloblasticChildChild, PreschoolFemaleHeterozygoteHumansInfantIntellectual DisabilityMaleMultienzyme ComplexesMutationOrotate PhosphoribosyltransferaseOrotic AcidOrotidine-5'-Phosphate DecarboxylasePurine-Pyrimidine Metabolism, Inborn ErrorsPyrimidinesMultienzyme ComplexesOrotate PhosphoribosyltransferaseOrotic AcidOrotidine-5'-Phosphate DecarboxylasepyrimidinePyrimidinesUridineuridine 5'-monophosphate synthase

Identifiers

PMID28205048
PMCPMC5393157
OpenAlexW2589130425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.